Skip to main content
Erschienen in:

01.12.2014 | Myeloproliferative Disorders (C Harrison, Section Editor)

Epidemiology of MPN: What Do We Know?

verfasst von: L. A. Anderson, M. F. McMullin

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

The myeloproliferative neoplasms, are characterised by overproduction of myeloid cells. Chronic myeloid leukaemia, polycythaemia vera, essential thrombocythaemia, myelofibrosis and the very rare disorders chronic neutrophilic leukaemia, chronic eosinophilic leukaemia not otherwise specified and mastocytosis are all included in the group. Incidence and prevalence rates reported in the worldwide literature are presented in this review. Survival data on each condition is described. Information on the aetiology of the disorders is discussed including body mass index, diet, smoking and alcohol, allergies, associated medical conditions, occupation and environmental exposures with focus on recent new studies. The aetiology of the myeloproliferative neoplasms remains unknown, and this review of the current state of knowledge highlights the need for further comprehensive research.
Literatur
1.
Zurück zum Zitat Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissue. Lyon: IARC; 2008. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissue. Lyon: IARC; 2008.
2.
Zurück zum Zitat James C, Ugo V, Le Couédic J-P, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–8.PubMed James C, Ugo V, Le Couédic J-P, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–8.PubMed
3.
Zurück zum Zitat Mc Lornan DP, Percy MJ, Jones AV, Cross NCP, Mc Mullin MF. Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation. Haematologica. 2005;90:1696–7.PubMed Mc Lornan DP, Percy MJ, Jones AV, Cross NCP, Mc Mullin MF. Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation. Haematologica. 2005;90:1696–7.PubMed
4.
Zurück zum Zitat Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459–68.PubMedCentralPubMed Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459–68.PubMedCentralPubMed
5.
Zurück zum Zitat Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472–6.PubMed Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472–6.PubMed
6.
Zurück zum Zitat Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008;112:141–9.PubMed Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008;112:141–9.PubMed
7.
Zurück zum Zitat Grand FH, Hidalgo-Curtis CE, Ernst T, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009;113:6182–92.PubMed Grand FH, Hidalgo-Curtis CE, Ernst T, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009;113:6182–92.PubMed
8.
Zurück zum Zitat Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360:2289–301.PubMed Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360:2289–301.PubMed
9.••
Zurück zum Zitat Klampfl T, Gisslinger H, Harutyunyan AS, Them NC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391–405. In this issue of the journal CALR, mutations were described by two groups for the first time in patients with myeloproliferative neoplasms who were negative for the previously discovered acquired mutations. Thus, a new acquired clone was demonstrated in these patients. Klampfl T, Gisslinger H, Harutyunyan AS, Them NC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391–405. In this issue of the journal CALR, mutations were described by two groups for the first time in patients with myeloproliferative neoplasms who were negative for the previously discovered acquired mutations. Thus, a new acquired clone was demonstrated in these patients.
10.
Zurück zum Zitat Lasho TL, Elliott MA, Pardanani A, Tefferi A. CALR mutation studies in chronic neutrophilic leukemia. Am J Hematol. 2014;89:450.PubMed Lasho TL, Elliott MA, Pardanani A, Tefferi A. CALR mutation studies in chronic neutrophilic leukemia. Am J Hematol. 2014;89:450.PubMed
11.
Zurück zum Zitat Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson RA, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia. 2013;27:1870–3.PubMedCentralPubMed Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson RA, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia. 2013;27:1870–3.PubMedCentralPubMed
12.
Zurück zum Zitat Kristensen T, Vestergaard H, Møller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn. 2011;13:180–8.PubMedCentralPubMed Kristensen T, Vestergaard H, Møller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn. 2011;13:180–8.PubMedCentralPubMed
13.
Zurück zum Zitat Broccia G, Deplano W, Dessalvi P, et al. Hematological malignancies in the island of Sardinia, 1974-1993: age and sex distributions and temporal changes in incidence. Hematol Oncol. 2004;22:91–109.PubMed Broccia G, Deplano W, Dessalvi P, et al. Hematological malignancies in the island of Sardinia, 1974-1993: age and sex distributions and temporal changes in incidence. Hematol Oncol. 2004;22:91–109.PubMed
14.
Zurück zum Zitat Johansson P, Kutti J, Andréasson B, et al. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-99. J Intern Med. 2004;256:161–5.PubMed Johansson P, Kutti J, Andréasson B, et al. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-99. J Intern Med. 2004;256:161–5.PubMed
15.••
Zurück zum Zitat Titmarsh GJ, Duncombe AS, McMullin MF, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2014;89(6):581–7. This paper analyses all published information on incidence and prevalence of myeloproliferative neoplasms and derives composite figures for each disorder from the information.PubMed Titmarsh GJ, Duncombe AS, McMullin MF, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2014;89(6):581–7. This paper analyses all published information on incidence and prevalence of myeloproliferative neoplasms and derives composite figures for each disorder from the information.PubMed
16.
Zurück zum Zitat Nennecke A, Wienecke A, Kraywinkel K. Leukemia incidence and survival in Germany according to current standardized categories. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014;57:93–102.PubMed Nennecke A, Wienecke A, Kraywinkel K. Leukemia incidence and survival in Germany according to current standardized categories. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014;57:93–102.PubMed
17.
Zurück zum Zitat Chen Y, Wang H, Kantarjian H, Cortes J. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma. 2013;54:1411–7.PubMed Chen Y, Wang H, Kantarjian H, Cortes J. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma. 2013;54:1411–7.PubMed
18.
Zurück zum Zitat Bhayat F, Das-Gupta E, Smith C, McKeever T, Hubbard R. The incidence of and mortality from leukaemias in the UK: a general population-based study. BMC Cancer. 2009;9:252.PubMedCentralPubMed Bhayat F, Das-Gupta E, Smith C, McKeever T, Hubbard R. The incidence of and mortality from leukaemias in the UK: a general population-based study. BMC Cancer. 2009;9:252.PubMedCentralPubMed
19.
Zurück zum Zitat Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724–34.PubMed Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724–34.PubMed
20.
Zurück zum Zitat Radivoyevitch T, Jankovic GM, Tiu RV, et al. Sex differences in the incidence of chronic myeloid leukemia. Radiat Environ Biophys. 2014;53:55–63.PubMed Radivoyevitch T, Jankovic GM, Tiu RV, et al. Sex differences in the incidence of chronic myeloid leukemia. Radiat Environ Biophys. 2014;53:55–63.PubMed
21.
Zurück zum Zitat Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012;118:3123–7.PubMedCentralPubMed Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012;118:3123–7.PubMedCentralPubMed
22.
Zurück zum Zitat Kurita S. Epidemiological studies of polycythemia vera in Japan (author’s transl). Nihon Ketsueki Gakkai Zasshi. 1974;37:793–5.PubMed Kurita S. Epidemiological studies of polycythemia vera in Japan (author’s transl). Nihon Ketsueki Gakkai Zasshi. 1974;37:793–5.PubMed
23.
Zurück zum Zitat Chaiter Y, Brenner B, Aghai E, Tatarsky I. High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. Leuk Lymphoma. 1992;7:251–5.PubMed Chaiter Y, Brenner B, Aghai E, Tatarsky I. High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. Leuk Lymphoma. 1992;7:251–5.PubMed
24.
Zurück zum Zitat Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008;112:45–52.PubMed Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008;112:45–52.PubMed
25.
Zurück zum Zitat Phekoo KJ, Richards MA, Møller H, Schey SA. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Haematologica. 2006;91:1400–4.PubMed Phekoo KJ, Richards MA, Møller H, Schey SA. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Haematologica. 2006;91:1400–4.PubMed
26.
Zurück zum Zitat Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment. Leuk Res. 2007;31:737–40.PubMed Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment. Leuk Res. 2007;31:737–40.PubMed
27.
Zurück zum Zitat Modan B. An epidemiological study of polycythemia vera. Blood. 1965;26:657–67.PubMed Modan B. An epidemiological study of polycythemia vera. Blood. 1965;26:657–67.PubMed
28.
Zurück zum Zitat Jensen MK, de Nully BP, Nielsen OJ, Hasselbalch HC. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol. 2000;65:132–9.PubMed Jensen MK, de Nully BP, Nielsen OJ, Hasselbalch HC. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol. 2000;65:132–9.PubMed
29.
Zurück zum Zitat Woodliff HJ, Dougan L. Myelofibrosis in Western Australia: an epidemiological study of 29 cases. Med J Aust. 1976;1:523–5.PubMed Woodliff HJ, Dougan L. Myelofibrosis in Western Australia: an epidemiological study of 29 cases. Med J Aust. 1976;1:523–5.PubMed
30.•
Zurück zum Zitat Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014;92:289–97. This is a systematic study of literature and databases to elucidate information on incidence and prevalence of myeloproliferative neoplasms in Europe.PubMed Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014;92:289–97. This is a systematic study of literature and databases to elucidate information on incidence and prevalence of myeloproliferative neoplasms in Europe.PubMed
31.
Zurück zum Zitat Bittencourt RI, Vassallo J, Chauffaille ML, et al. Philadelphia-negative chronic myeloproliferative neoplasms. Rev Bras Hematol Hemoter. 2012;34:140–9.PubMedCentralPubMed Bittencourt RI, Vassallo J, Chauffaille ML, et al. Philadelphia-negative chronic myeloproliferative neoplasms. Rev Bras Hematol Hemoter. 2012;34:140–9.PubMedCentralPubMed
32.
Zurück zum Zitat Cohen SS, Skovbo S, Vestergaard H, et al. Epidemiology of systemic mastocytosis in Denmark. Br J Haemat. 2014;166:521–8. Cohen SS, Skovbo S, Vestergaard H, et al. Epidemiology of systemic mastocytosis in Denmark. Br J Haemat. 2014;166:521–8.
33.
Zurück zum Zitat Valent P. Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology. Am J Cancer Res. 2013;3:159–72.PubMedCentralPubMed Valent P. Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology. Am J Cancer Res. 2013;3:159–72.PubMedCentralPubMed
34.
Zurück zum Zitat Maynadié M, De Angelis R, Marcos-Gragera R, et al. Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study. Haematologica. 2013;98:230–8.PubMedCentralPubMed Maynadié M, De Angelis R, Marcos-Gragera R, et al. Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study. Haematologica. 2013;98:230–8.PubMedCentralPubMed
35.
Zurück zum Zitat Sant M, Minicozzi P, Mounier M, et al. Remarkable survival improvements for haematological malignancies highlighted by the EUROCARE population based registries from late nineties to 2008. Lancet Oncol 2014; (in press). Sant M, Minicozzi P, Mounier M, et al. Remarkable survival improvements for haematological malignancies highlighted by the EUROCARE population based registries from late nineties to 2008. Lancet Oncol 2014; (in press).
36.
Zurück zum Zitat Brunner AM, Campigotto F, Sadrzadeh H, et al. Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2013;119:2620–9.PubMed Brunner AM, Campigotto F, Sadrzadeh H, et al. Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2013;119:2620–9.PubMed
37.
Zurück zum Zitat Smith AG, Painter D, Howell DA, et al. Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort. BMJ Open. 2014;4:e004266.PubMedCentralPubMed Smith AG, Painter D, Howell DA, et al. Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort. BMJ Open. 2014;4:e004266.PubMedCentralPubMed
38.
Zurück zum Zitat Mandal R, Bolt DM, Shah BK. Disparities in chronic myeloid leukemia survival by age, gender, and ethnicity in pre- and post-imatinib eras in the US. Acta Oncol. 2013;52:837–41.PubMed Mandal R, Bolt DM, Shah BK. Disparities in chronic myeloid leukemia survival by age, gender, and ethnicity in pre- and post-imatinib eras in the US. Acta Oncol. 2013;52:837–41.PubMed
39.
Zurück zum Zitat Castagnetti F, Palandri F, Amabile M, et al. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood. 2009;113:3428–34.PubMed Castagnetti F, Palandri F, Amabile M, et al. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood. 2009;113:3428–34.PubMed
40.
Zurück zum Zitat Hultcrantz M, Kristinsson SY, Andersson TM-L, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012;30:2995–3001.PubMedCentralPubMed Hultcrantz M, Kristinsson SY, Andersson TM-L, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012;30:2995–3001.PubMedCentralPubMed
41.
Zurück zum Zitat Cherry M, Cardenas-Turanzas M, Pham H, et al. Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome. Leuk Res. 2013;37:1472–6.PubMed Cherry M, Cardenas-Turanzas M, Pham H, et al. Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome. Leuk Res. 2013;37:1472–6.PubMed
42.
Zurück zum Zitat Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874–81.PubMedCentralPubMed Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874–81.PubMedCentralPubMed
43.
Zurück zum Zitat Bonicelli G, Abdulkarim K, Mounier M, et al. Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients. Br J Haematol. 2013;160:251–4.PubMed Bonicelli G, Abdulkarim K, Mounier M, et al. Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients. Br J Haematol. 2013;160:251–4.PubMed
44.
Zurück zum Zitat Montanaro M, Latagliata R, Cedrone M, et al. Thrombosis and survival in essential thrombocythemia: a regional study of 1144 patients. Am J Hematol. 2014;89:542–6.PubMed Montanaro M, Latagliata R, Cedrone M, et al. Thrombosis and survival in essential thrombocythemia: a regional study of 1144 patients. Am J Hematol. 2014;89:542–6.PubMed
45.
Zurück zum Zitat Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the international working group on myelofibrosis research and treatment. Blood. 2012;120:1197–201.PubMed Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the international working group on myelofibrosis research and treatment. Blood. 2012;120:1197–201.PubMed
46.
Zurück zum Zitat Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123:1552–6.PubMed Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123:1552–6.PubMed
47.
Zurück zum Zitat Cervantes F, Dupriez B, Passamonti F, et al. Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol. 2012;30:2981–7.PubMed Cervantes F, Dupriez B, Passamonti F, et al. Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol. 2012;30:2981–7.PubMed
48.
Zurück zum Zitat Pardanani A, Lasho TL, Finke CM, et al. Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. J Clin Oncol. 2012;30:1087–94.PubMed Pardanani A, Lasho TL, Finke CM, et al. Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. J Clin Oncol. 2012;30:1087–94.PubMed
49.
Zurück zum Zitat Barbui T, Carobbio A, Finazzi G, et al. Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. Leukemia. 2013;27:2084–6.PubMed Barbui T, Carobbio A, Finazzi G, et al. Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. Leukemia. 2013;27:2084–6.PubMed
50.
Zurück zum Zitat Helbig G, Wieczorkiewicz A, Woźniczka K, et al. The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis. Med Oncol. 2012;29:2379–84.PubMed Helbig G, Wieczorkiewicz A, Woźniczka K, et al. The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis. Med Oncol. 2012;29:2379–84.PubMed
51.
Zurück zum Zitat Martínez-Trillos A, Maffioli M, Colomer D, et al. Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis. Ann Hematol. 2014;93:797–802.PubMed Martínez-Trillos A, Maffioli M, Colomer D, et al. Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis. Ann Hematol. 2014;93:797–802.PubMed
52.
Zurück zum Zitat Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27:1861–9.PubMed Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27:1861–9.PubMed
53.
Zurück zum Zitat Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014;28:1494–500.PubMed Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014;28:1494–500.PubMed
54.
Zurück zum Zitat Lekovic D, Gotic M, Perunicic-Jovanovic M, et al. Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis. Med Oncol. 2014;31:869.PubMed Lekovic D, Gotic M, Perunicic-Jovanovic M, et al. Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis. Med Oncol. 2014;31:869.PubMed
55.
Zurück zum Zitat Mascarenhas J, Hoffman R. A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood. 2013;121:4832–7.PubMed Mascarenhas J, Hoffman R. A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood. 2013;121:4832–7.PubMed
56.
Zurück zum Zitat Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013;98:1865–71.PubMedCentralPubMed Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013;98:1865–71.PubMedCentralPubMed
57.
Zurück zum Zitat Wang JS, Ho CH, Lin CK. Chronic neutrophilic leukemia—report of a case and review of the literature. Zhonghua Yi Xue Za Zhi (Taipei). 1990;46:109–12. Wang JS, Ho CH, Lin CK. Chronic neutrophilic leukemia—report of a case and review of the literature. Zhonghua Yi Xue Za Zhi (Taipei). 1990;46:109–12.
58.
Zurück zum Zitat Elliott MA, Hanson CA, Dewald GW, Smoley SA, Lasho TL, Tefferi A. WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia. 2005;19:313–7.PubMed Elliott MA, Hanson CA, Dewald GW, Smoley SA, Lasho TL, Tefferi A. WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia. 2005;19:313–7.PubMed
59.
Zurück zum Zitat Reilly JT. Chronic neutrophilic leukaemia: a distinct clinical entity? Br J Haematol. 2002;116:10–8.PubMed Reilly JT. Chronic neutrophilic leukaemia: a distinct clinical entity? Br J Haematol. 2002;116:10–8.PubMed
60.
Zurück zum Zitat Damaj G, Joris M, Chandesris O, et al. ASXL1 and not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS ONE. 2014;9:e85362.PubMedCentralPubMed Damaj G, Joris M, Chandesris O, et al. ASXL1 and not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS ONE. 2014;9:e85362.PubMedCentralPubMed
61.
Zurück zum Zitat Escribano L, Alvarez-Twose I, Sanchez-Munoz L, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish network on mastocytosis in a series of 145 patients. J Allergy Clin Immunol. 2009;124:514521. Escribano L, Alvarez-Twose I, Sanchez-Munoz L, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish network on mastocytosis in a series of 145 patients. J Allergy Clin Immunol. 2009;124:514521.
62.••
Zurück zum Zitat Murphy F, Kroll ME, Pirie K, Reeves G, Green J, Beral V. Body size in relation to incidence of subtypes of haematological malignancy in the prospective Million Women Study. Br J Cancer. 2013;108:2390–8. A cohort of over a million women in the UK were followed for 10 years providing a wealth of data. Incident cancer was ascertained. This paper looks at haematological malignancy and body size and height and what associations occur.PubMedCentralPubMed Murphy F, Kroll ME, Pirie K, Reeves G, Green J, Beral V. Body size in relation to incidence of subtypes of haematological malignancy in the prospective Million Women Study. Br J Cancer. 2013;108:2390–8. A cohort of over a million women in the UK were followed for 10 years providing a wealth of data. Incident cancer was ascertained. This paper looks at haematological malignancy and body size and height and what associations occur.PubMedCentralPubMed
63.
Zurück zum Zitat Kabat GC, Wu JW, Moore SC, et al. Lifestyle and dietary factors in relation to risk of chronic myeloid leukemia in the NIH-AARP diet and health study. Cancer Epidemiol Biomarkers Prev. 2013;22:848–54.PubMed Kabat GC, Wu JW, Moore SC, et al. Lifestyle and dietary factors in relation to risk of chronic myeloid leukemia in the NIH-AARP diet and health study. Cancer Epidemiol Biomarkers Prev. 2013;22:848–54.PubMed
64.•
Zurück zum Zitat Saberi Hosnijeh F, Romieu I, et al. Anthropometric characteristics and risk of lymphoid and myeloid leukemia in the European prospective investigation into cancer and nutrition (EPIC). Cancer Causes Control. 2013;24:427–38. A study investigating the association between cancer and nutrition following patients in 10 European countries. There were 671 patients with leukaemia followed for a median of 11.5 years and the relationships with anthropomorphic characteristics are studied in the paper.PubMed Saberi Hosnijeh F, Romieu I, et al. Anthropometric characteristics and risk of lymphoid and myeloid leukemia in the European prospective investigation into cancer and nutrition (EPIC). Cancer Causes Control. 2013;24:427–38. A study investigating the association between cancer and nutrition following patients in 10 European countries. There were 671 patients with leukaemia followed for a median of 11.5 years and the relationships with anthropomorphic characteristics are studied in the paper.PubMed
65.
Zurück zum Zitat Larsson SC, Wolk A. Overweight and obesity and incidence of leukemia: a meta-analysis of cohort studies. Int J Cancer. 2008;122:1418–21.PubMed Larsson SC, Wolk A. Overweight and obesity and incidence of leukemia: a meta-analysis of cohort studies. Int J Cancer. 2008;122:1418–21.PubMed
66.
Zurück zum Zitat Engeland A, Tretli S, Hansen S, Bjørge T. Height and body mass index and risk of lymphohematopoietic malignancies in two million Norwegian men and women. Am J Epidemiol. 2007;165:44–52.PubMed Engeland A, Tretli S, Hansen S, Bjørge T. Height and body mass index and risk of lymphohematopoietic malignancies in two million Norwegian men and women. Am J Epidemiol. 2007;165:44–52.PubMed
67.
Zurück zum Zitat Kasim K, Levallois P, Abdous B, Auger P, Johnson KC. Lifestyle factors and the risk of adult leukemia in Canada. Cancer Causes Control. 2005;16:489–500.PubMed Kasim K, Levallois P, Abdous B, Auger P, Johnson KC. Lifestyle factors and the risk of adult leukemia in Canada. Cancer Causes Control. 2005;16:489–500.PubMed
68.
Zurück zum Zitat Strom SS, Yamamura Y, Kantarijian HM, Cortes-Franco JE. Obesity, weight gain, and risk of chronic myeloid leukemia. Cancer Epidemiol Biomarkers Prev. 2009;18:1501–6.PubMedCentralPubMed Strom SS, Yamamura Y, Kantarijian HM, Cortes-Franco JE. Obesity, weight gain, and risk of chronic myeloid leukemia. Cancer Epidemiol Biomarkers Prev. 2009;18:1501–6.PubMedCentralPubMed
69.
Zurück zum Zitat Leal AD, Thompson CA, Wang AH, Vierkant RA, Habermann TM, Ross JA, et al. Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women’s Health Study cohort. Int J Cancer. 2014;134:1741–50.PubMed Leal AD, Thompson CA, Wang AH, Vierkant RA, Habermann TM, Ross JA, et al. Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women’s Health Study cohort. Int J Cancer. 2014;134:1741–50.PubMed
70.
Zurück zum Zitat Kasim K, Johnson KC, Levallois P, Abdous B, Auger P. Recreational physical activity and the risk of adult leukemia in Canada. Cancer Causes Control. 2009;20:1377–86.PubMed Kasim K, Johnson KC, Levallois P, Abdous B, Auger P. Recreational physical activity and the risk of adult leukemia in Canada. Cancer Causes Control. 2009;20:1377–86.PubMed
71.•
Zurück zum Zitat Saberi Hosnijeh F, Peeters P, Romieu I, et al. Dietary intakes and risk of lymphoid and myeloid leukemia in the European prospective investigation into cancer and nutrition (EPIC). Nutr Cancer. 2014;66:14–28. This paper looks in detail at a large number of dietary factors in this very extensively investigated cohort of European patients and explores any links to the haematological malignancy.PubMed Saberi Hosnijeh F, Peeters P, Romieu I, et al. Dietary intakes and risk of lymphoid and myeloid leukemia in the European prospective investigation into cancer and nutrition (EPIC). Nutr Cancer. 2014;66:14–28. This paper looks in detail at a large number of dietary factors in this very extensively investigated cohort of European patients and explores any links to the haematological malignancy.PubMed
72.
Zurück zum Zitat Musselman JRB, Blair CK, Cerhan JR, Nguyen P, Hirsch B, Ross JA. Risk of adult acute and chronic myeloid leukemia with cigarette smoking and cessation. Cancer Epidemiol. 2013;37:410–6.PubMed Musselman JRB, Blair CK, Cerhan JR, Nguyen P, Hirsch B, Ross JA. Risk of adult acute and chronic myeloid leukemia with cigarette smoking and cessation. Cancer Epidemiol. 2013;37:410–6.PubMed
73.
Zurück zum Zitat Richardson DB, Terschüren C, Pohlabeln H, Jöckel K-H, Hoffmann W. Temporal patterns of association between cigarette smoking and leukemia risk. Cancer Causes Control. 2008;19:43–50.PubMed Richardson DB, Terschüren C, Pohlabeln H, Jöckel K-H, Hoffmann W. Temporal patterns of association between cigarette smoking and leukemia risk. Cancer Causes Control. 2008;19:43–50.PubMed
74.
Zurück zum Zitat Björk J, Albin M, Welinder H, et al. Are occupational, hobby, or lifestyle exposures associated with Philadelphia chromosome positive chronic myeloid leukaemia? Occup Environ Med. 2001;58:722–7.PubMedCentralPubMed Björk J, Albin M, Welinder H, et al. Are occupational, hobby, or lifestyle exposures associated with Philadelphia chromosome positive chronic myeloid leukaemia? Occup Environ Med. 2001;58:722–7.PubMedCentralPubMed
75.••
Zurück zum Zitat Kroll ME, Murphy F, Pirie K, Reeves GK, Green J, Beral V. Alcohol drinking, tobacco smoking and subtypes of haematological malignancy in the UK million women study. Br J Cancer. 2012;107:879–87. Looking at degrees of alcohol and tobacco consumption and relationship to haematological malignancy in this 1.3 million group of women, the size and extent of this vast study provides useful evidence.PubMedCentralPubMed Kroll ME, Murphy F, Pirie K, Reeves GK, Green J, Beral V. Alcohol drinking, tobacco smoking and subtypes of haematological malignancy in the UK million women study. Br J Cancer. 2012;107:879–87. Looking at degrees of alcohol and tobacco consumption and relationship to haematological malignancy in this 1.3 million group of women, the size and extent of this vast study provides useful evidence.PubMedCentralPubMed
76.
Zurück zum Zitat Mele A, Visani G, Pulsoni A, Monarca B, Castelli G, Stazi MA, et al. Risk factors for essential thrombocythemia: a case-control study. Italian leukemia study group. Cancer. 1996;77:2157–61.PubMed Mele A, Visani G, Pulsoni A, Monarca B, Castelli G, Stazi MA, et al. Risk factors for essential thrombocythemia: a case-control study. Italian leukemia study group. Cancer. 1996;77:2157–61.PubMed
77.
Zurück zum Zitat Gorini G, Stagnaro E, Fontana V, Miligi L, Ramazzotti V, Nanni O, et al. Alcohol consumption and risk of leukemia: a multicenter case-control study. Leuk Res. 2007;31:379–86.PubMed Gorini G, Stagnaro E, Fontana V, Miligi L, Ramazzotti V, Nanni O, et al. Alcohol consumption and risk of leukemia: a multicenter case-control study. Leuk Res. 2007;31:379–86.PubMed
78.
Zurück zum Zitat Shadman M, White E, De Roos AJ, Walter RB. Associations between allergies and risk of hematologic malignancies: results from the VITamins And Lifestyle cohort study. Am J Hematol. 2013;88:1050–4.PubMed Shadman M, White E, De Roos AJ, Walter RB. Associations between allergies and risk of hematologic malignancies: results from the VITamins And Lifestyle cohort study. Am J Hematol. 2013;88:1050–4.PubMed
79.
Zurück zum Zitat Quinlan SC, Morton LM, Pfeiffer RM, et al. Increased risk for lymphoid and myeloid neoplasms in elderly solid-organ transplant recipients. Cancer Epidemiol Biomarkers Prev. 2010;19:1229–37.PubMedCentralPubMed Quinlan SC, Morton LM, Pfeiffer RM, et al. Increased risk for lymphoid and myeloid neoplasms in elderly solid-organ transplant recipients. Cancer Epidemiol Biomarkers Prev. 2010;19:1229–37.PubMedCentralPubMed
80.
Zurück zum Zitat Shebl FM, Warren JL, Eggers PW, Engels EA. Cancer risk among elderly persons with end-stage renal disease: a population-based case-control study. BMC Nephrol. 2012;13:65.PubMedCentralPubMed Shebl FM, Warren JL, Eggers PW, Engels EA. Cancer risk among elderly persons with end-stage renal disease: a population-based case-control study. BMC Nephrol. 2012;13:65.PubMedCentralPubMed
81.•
Zurück zum Zitat Titmarsh GJ, McMullin MF, McShane CM, Clarke M, Engels EA, Anderson LA. Community-acquired infections and their association with myeloid malignancies. Cancer Epidemiol. 2013;38:56–61. The SEER database has extensive information on medical conditions in a very large group. This paper interrogates the database to investigate for infections and associations with myeloid malignancy prior to diagnosis. A number of interesting associations are discovered.PubMed Titmarsh GJ, McMullin MF, McShane CM, Clarke M, Engels EA, Anderson LA. Community-acquired infections and their association with myeloid malignancies. Cancer Epidemiol. 2013;38:56–61. The SEER database has extensive information on medical conditions in a very large group. This paper interrogates the database to investigate for infections and associations with myeloid malignancy prior to diagnosis. A number of interesting associations are discovered.PubMed
82.
Zurück zum Zitat Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer. 2009;100:822–8.PubMedCentralPubMed Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer. 2009;100:822–8.PubMedCentralPubMed
83.
Zurück zum Zitat Anderson LA, Pfeiffer R, Warren JL, et al. Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev. 2008;17:3069–75.PubMedCentralPubMed Anderson LA, Pfeiffer R, Warren JL, et al. Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev. 2008;17:3069–75.PubMedCentralPubMed
84.
Zurück zum Zitat Gentile G, Mele A, Monarco B, et al. Hepatitis B and C viruses, human T-cell lymphotropic virus types I and II, and leukemias: a case-control study. Ital Leuk Study Group Cancer Epidemiol Biomark Prev. 1996;5:227–30. Gentile G, Mele A, Monarco B, et al. Hepatitis B and C viruses, human T-cell lymphotropic virus types I and II, and leukemias: a case-control study. Ital Leuk Study Group Cancer Epidemiol Biomark Prev. 1996;5:227–30.
85.
Zurück zum Zitat Zheng W, Linet MS, Shu XO, Pan RP, Gao YT, Fraumeni JF. Prior medical conditions and the risk of adult leukemia in Shanghai, People’s Republic of China. Cancer Causes Control. 1993;4:361–8.PubMed Zheng W, Linet MS, Shu XO, Pan RP, Gao YT, Fraumeni JF. Prior medical conditions and the risk of adult leukemia in Shanghai, People’s Republic of China. Cancer Causes Control. 1993;4:361–8.PubMed
86.
Zurück zum Zitat Johnson KJ, Blair CM, Fink JM, et al. Medical conditions and risk of adult myeloid leukemia. Cancer Causes Control. 2012;23:1083–9.PubMedCentralPubMed Johnson KJ, Blair CM, Fink JM, et al. Medical conditions and risk of adult myeloid leukemia. Cancer Causes Control. 2012;23:1083–9.PubMedCentralPubMed
87.
Zurück zum Zitat Howard RA, Gilbert ES, Chen BE, et al. Leukemia following breast cancer: an international population-based study of 376,825 women. Breast Cancer Res Treat. 2007;105:359–68.PubMed Howard RA, Gilbert ES, Chen BE, et al. Leukemia following breast cancer: an international population-based study of 376,825 women. Breast Cancer Res Treat. 2007;105:359–68.PubMed
88.
Zurück zum Zitat Pizzolito S, Barbone F, Rizzi C, Scott A, Piemonte M, Beltrami C. Parathyroid adenomas and malignant neoplasms: coincidence or etiological association? Adv Clin Path. 1997;1:275–80.PubMed Pizzolito S, Barbone F, Rizzi C, Scott A, Piemonte M, Beltrami C. Parathyroid adenomas and malignant neoplasms: coincidence or etiological association? Adv Clin Path. 1997;1:275–80.PubMed
89.
Zurück zum Zitat Khalade A, Jaakkola MS, Pukkala E, Jaakkola JJ. Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis. Envir Health. 2010;9:31. Khalade A, Jaakkola MS, Pukkala E, Jaakkola JJ. Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis. Envir Health. 2010;9:31.
90.
Zurück zum Zitat Vlaanderen J, Lan Q, Kromhout H, Rothman N, Vermeulen R. Occupational benzene exposure and the risk of chronic myeloid leukemia: a meta-analysis of cohort studies incorporating study quality dimensions. Am J Ind Med. 2012;55:779–85.PubMed Vlaanderen J, Lan Q, Kromhout H, Rothman N, Vermeulen R. Occupational benzene exposure and the risk of chronic myeloid leukemia: a meta-analysis of cohort studies incorporating study quality dimensions. Am J Ind Med. 2012;55:779–85.PubMed
91.
Zurück zum Zitat Glass DC, Schnatter AR, Tang G, Irons RD, Rushton L. Risk of myeloproliferative disease and chronic myeloid leukaemia following exposure to low-level benzene in a nested case-control study of petroleum workers. Occup Environ Med. 2014;71:266–74.PubMed Glass DC, Schnatter AR, Tang G, Irons RD, Rushton L. Risk of myeloproliferative disease and chronic myeloid leukaemia following exposure to low-level benzene in a nested case-control study of petroleum workers. Occup Environ Med. 2014;71:266–74.PubMed
92.
Zurück zum Zitat Terreros M. Exposure to occupational and environmental risk factors in hematologic disorders. Neoplasia. 1997;14:133–6. Terreros M. Exposure to occupational and environmental risk factors in hematologic disorders. Neoplasia. 1997;14:133–6.
93.••
Zurück zum Zitat Anderson LA, Duncombe AS, Hughes M, Mills ME, Wilson JC, McMullin MF. Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. Am J Hematol. 2012;87:175–82. In this study, all the published literature on the aetiology of myeloproliferative neoplasms is analyzed and findings are summarised and presented.PubMed Anderson LA, Duncombe AS, Hughes M, Mills ME, Wilson JC, McMullin MF. Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. Am J Hematol. 2012;87:175–82. In this study, all the published literature on the aetiology of myeloproliferative neoplasms is analyzed and findings are summarised and presented.PubMed
94.
Zurück zum Zitat Luckhaupt SE, Deapen D, Cress R, Schumacher P, Shen R, Calvert GM. Leukemia among male construction workers in California, 1988-2007. Leuk Lymphoma. 2012;53:2228–36.PubMed Luckhaupt SE, Deapen D, Cress R, Schumacher P, Shen R, Calvert GM. Leukemia among male construction workers in California, 1988-2007. Leuk Lymphoma. 2012;53:2228–36.PubMed
95.
Zurück zum Zitat Giles GG, Lickiss JN, Baikie MJ, Lowenthal RM, Panton J. Myeloproliferative and lymphoproliferative disorders in Tasmania, 1972-80: occupational and familial aspects. J Natl Cancer Inst. 1984;72:1233–40.PubMed Giles GG, Lickiss JN, Baikie MJ, Lowenthal RM, Panton J. Myeloproliferative and lymphoproliferative disorders in Tasmania, 1972-80: occupational and familial aspects. J Natl Cancer Inst. 1984;72:1233–40.PubMed
96.
Zurück zum Zitat Van Maele-Fabry G, Duhayon S, Lison D. A systematic review of myeloid leukemias and occupational pesticide exposure. Cancer Causes Control. 2007;18:457–78.PubMed Van Maele-Fabry G, Duhayon S, Lison D. A systematic review of myeloid leukemias and occupational pesticide exposure. Cancer Causes Control. 2007;18:457–78.PubMed
97.
Zurück zum Zitat Falcetta R, Sacerdote C, Bazzan M, et al. Occupational and environmental risk factors for essential thrombocythemia: a case-control study. G Ital Med Lav Ergon. 2014;25:9–12. Falcetta R, Sacerdote C, Bazzan M, et al. Occupational and environmental risk factors for essential thrombocythemia: a case-control study. G Ital Med Lav Ergon. 2014;25:9–12.
98.
Zurück zum Zitat Pasqualetti P, Casale R, Colantonio D, Collacciani A. Occupational risk for hematological malignancies. Am J Hematol. 1991;38:147–9.PubMed Pasqualetti P, Casale R, Colantonio D, Collacciani A. Occupational risk for hematological malignancies. Am J Hematol. 1991;38:147–9.PubMed
99.
Zurück zum Zitat Sorahan T. Magnetic fields and leukaemia risks in UK electricity supply workers. Occup Med (Lond). 2014;64:157–65. Sorahan T. Magnetic fields and leukaemia risks in UK electricity supply workers. Occup Med (Lond). 2014;64:157–65.
100.
Zurück zum Zitat Feychting M, Ahlbom A. Magnetic fields, leukemia, and central nervous system tumors in Swedish adults residing near high-voltage power lines. Epidemiology. 1994;5:501–9.PubMed Feychting M, Ahlbom A. Magnetic fields, leukemia, and central nervous system tumors in Swedish adults residing near high-voltage power lines. Epidemiology. 1994;5:501–9.PubMed
101.
Zurück zum Zitat Feychting M, Forssén U, Floderus B. Occupational and residential magnetic field exposure and leukemia and central nervous system tumors. Epidemiology. 1997;8:384–9.PubMed Feychting M, Forssén U, Floderus B. Occupational and residential magnetic field exposure and leukemia and central nervous system tumors. Epidemiology. 1997;8:384–9.PubMed
102.
Zurück zum Zitat Hsu W-L, Preston DL, Soda M, Sugiyama H, Funamoto S, Kodama K, et al. The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001. Radiat Res. 2013;179:361–82.PubMed Hsu W-L, Preston DL, Soda M, Sugiyama H, Funamoto S, Kodama K, et al. The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001. Radiat Res. 2013;179:361–82.PubMed
103.
Zurück zum Zitat Najean Y, Rain JD, Billotey C. Epidemiological data in polycythaemia vera: a study of 842 cases. Hematol Cell Ther. 1998;40:159–65.PubMed Najean Y, Rain JD, Billotey C. Epidemiological data in polycythaemia vera: a study of 842 cases. Hematol Cell Ther. 1998;40:159–65.PubMed
104.
Zurück zum Zitat Merk K, Mattsson B, Mattsson A, Holm G, Gullbring B, Björkholm M. The incidence of cancer among blood donors. Int J Epidemiol. 1990;19:505–9.PubMed Merk K, Mattsson B, Mattsson A, Holm G, Gullbring B, Björkholm M. The incidence of cancer among blood donors. Int J Epidemiol. 1990;19:505–9.PubMed
105.
Zurück zum Zitat Magnussen K, Hasselbalch HC, Ullum H, Bjerrum OW. Characterization of blood donors with high haemoglobin concentration. Vox Sang. 2013;104:110–4.PubMed Magnussen K, Hasselbalch HC, Ullum H, Bjerrum OW. Characterization of blood donors with high haemoglobin concentration. Vox Sang. 2013;104:110–4.PubMed
Metadaten
Titel
Epidemiology of MPN: What Do We Know?
verfasst von
L. A. Anderson
M. F. McMullin
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 4/2014
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-014-0228-z

Neu im Fachgebiet Onkologie

KI erlaubt neue Einsichten in die Krebsprognose

Forschende sind in komplexen Real-World-Daten des Westdeutschen Tumorzentrums auf bisher weniger beachtete Zusammenhänge von bestimmten Risikomarkern mit der Prognose gestoßen. Möglich gemacht hat’s ein Verfahren namens „erklärbare KI“, mit dem sich hunderte Tumor- und Patientenmerkmale gleichzeitig betrachten lassen.

Körperlich fitte Krebskranke leben länger

Krebspatienten, auch und vor allem solche in fortgeschrittenen Stadien, profitieren offenbar von guter körperlicher Verfassung. Hohe Muskelkraft und kardiorespiratorische Fitness sind laut Ergebnissen einer Metaanalyse mit geringerer Mortalität assoziiert.

Kein (großer) Schutz vor Kolorektalkarzinom-Rezidiven durch ASS

Die erste Phase-3-Studie zum Nutzen von ASS in der adjuvanten Therapie des kolorektalen Karzinoms ist negativ verlaufen. Das abschließende Urteil über eine Sekundärprävention mit ASS ist trotzdem noch nicht gefallen.

Frühe CLL-Therapie: BTK-Hemmer verlängert EFS und PFS, aber nicht OS

Auch nach sechs Jahren ergibt sich kein Überlebensvorteil einer Therapie mit dem BTK-Hemmer Ibrutinib für Menschen mit frühem CLL-Stadium und erhöhtem Progressionsrisiko. Die Progressionsrate wird mit der Behandlung jedoch um über 80% gesenkt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.